← Leaderboards
Hui Zheng
Baylor College Of Medicine
$41,943,035
Attributed
$54,015,742
Total exposure
19
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$67,511,113 · 20
By mechanism
R01$27,963,502 · 9
P01$17,247,640 · 5
RF1$13,868,094 · 5
U01$8,431,877 · 1
Top collaborators
- Jin Wang9 shared
- Yueming Li5 shared
- Sheng Zhang5 shared
- Wei Cao2 shared
- Benjamin Deneen1 shared
- Meng Carla Wang1 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Aleksandar Milosavljevic$34,645,084
- Lindsay C Burrage$5,445,602
- James Francis Martin$25,967,418
- Andrew K Folick$91,634
- Owen R Hirschi$133,267
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseMouse ModelPathway InteractionsNeuronsPathologyPathogenesisMediatingInsightSignal TransductionIn VivoRegulationBrainBiochemicalBehavioralPhysiologicalKnock-In MouseTau ProteinsPlayPropertyMutantAgingIn VitroCells
Grant awards (101)
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease$2,555,846
P01 · FY2025 · AG · contact PI
The Role of the Complement Pathway in Alzheimer's Disease$765,279
R01 · FY2025 · AG · contact PI
Knockin mouse models of Alzheimer's Disease$764,341
R01 · FY2025 · AG · contact PI
ROLE OF TFEB IN TAUOPATHY$498,954
R01 · FY2025 · NS · contact PI
A TFEB and V-ATPase-mediated lysosomal stress sensing pathway in tauopathy$472,810
P01 · FY2025 · AG · contact PI
Administration and Data Integration Core$218,157
P01 · FY2025 · AG · contact PI
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease$104,795
P01 · FY2025 · AG · contact PI
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease$2,608,006
P01 · FY2024 · AG · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$804,669
U01 · FY2024 · AG
The Role of the Complement Pathway in Alzheimer's Disease$780,898
R01 · FY2024 · AG · contact PI
A TFEB and V-ATPase-mediated lysosomal stress sensing pathway in tauopathy$521,867
P01 · FY2024 · AG · contact PI
ROLE OF TFEB IN TAUOPATHY$498,954
R01 · FY2024 · NS · contact PI
Administration and Data Integration Core$240,792
P01 · FY2024 · AG · contact PI
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease$2,608,006
P01 · FY2023 · AG · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$1,023,733
U01 · FY2023 · AG
A TFEB and V-ATPase-mediated lysosomal stress sensing pathway in tauopathy$521,869
P01 · FY2023 · AG · contact PI
Administration and Data Integration Core$240,790
P01 · FY2023 · AG · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$234,288
U01 · FY2023 · AG
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease$42,568
P01 · FY2023 · AG · contact PI
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease$2,608,006
P01 · FY2022 · AG · contact PI
Knockin mouse models of Alzheimer's Disease$2,340,048
RF1 · FY2022 · AG · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$2,219,336
U01 · FY2022 · AG
A TFEB and V-ATPase-mediated lysosomal stress sensing pathway in tauopathy$513,147
P01 · FY2022 · AG · contact PI
Administration and Data Integration Core$260,179
P01 · FY2022 · AG · contact PI
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease$250,000
P01 · FY2022 · AG · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$249,942
U01 · FY2022 · AG
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease$85,138
P01 · FY2022 · AG · contact PI
Lysosome Regulation and Signaling in Aging and Alzheimer's Disease$2,633,006
P01 · FY2021 · AG · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$2,089,925
U01 · FY2021 · AG
ROLE OF TFEB IN TAUOPATHY$1,511,862
RF1 · FY2021 · NS · contact PI
Knockin Mouse Models of Alzheimer's Disease$565,122
R01 · FY2021 · AG · contact PI
Convergence of tauopathy and Huntington's disease through selective autophagy$558,425
R01 · FY2021 · AG · contact PI
A TFEB and V-ATPase-mediated lysosomal stress sensing pathway in tauopathy$521,869
P01 · FY2021 · AG · contact PI
Administration and Data Integration Core$240,789
P01 · FY2021 · AG · contact PI
Developing Novel Soluble Epoxide Hydrolase Inhibitors for the Treatment of Alzheimer's Disease$1,809,984
U01 · FY2020 · AG
Convergence of tauopathy and Huntington's disease through selective autophagy$567,167
R01 · FY2020 · AG · contact PI
Knockin Mouse Models of Alzheimer's Disease$565,122
R01 · FY2020 · AG · contact PI
Targeting a lipid-mediated pro-longevity pathway as Alzheimer's therapy$48,650
RF1 · FY2020 · AG · contact PI
Convergence of tauopathy and Huntington's disease through selective autophagy$575,653
R01 · FY2019 · AG · contact PI
Knockin Mouse Models of Alzheimer's Disease$565,122
R01 · FY2019 · AG · contact PI
Role of TFEB in Tauopathy$418,412
R01 · FY2019 · NS · contact PI
Targeting a lipid-mediated pro-longevity pathway as Alzheimer's therapy$3,942,988
RF1 · FY2018 · AG · contact PI
Interrogating the Interferon Pathway in Aging and Alzheimer's Disease$1,803,164
RF1 · FY2018 · AG
Interrogating the Interferon Pathway in Aging and Alzheimer's Disease$1,075,434
RF1 · FY2018 · AG
Convergence of tauopathy and Huntington's disease through selective autophagy$583,893
R01 · FY2018 · AG · contact PI
Knockin Mouse Models of Alzheimer's Disease$565,122
R01 · FY2018 · AG · contact PI
Role of TFEB in Tauopathy$416,777
R01 · FY2018 · NS · contact PI
Convergence of tauopathy and Huntington's disease through selective autophagy$606,517
R01 · FY2017 · AG · contact PI
Knockin Mouse Models of Alzheimer's Disease$565,122
R01 · FY2017 · AG · contact PI
Role of TFEB in Tauopathy$415,189
R01 · FY2017 · NS · contact PI
Pathophysiology of APP in vivo$396,943
R01 · FY2017 · AG · contact PI
Decoding the role of diverse astrocyte populations in aging and AD$3,145,948
RF1 · FY2016 · AG · contact PI
Role of TFEB in Tauopathy$411,224
R01 · FY2016 · NS · contact PI
Pathophysiology of APP in vivo$396,943
R01 · FY2016 · AG · contact PI
Knockin Mouse Models of Alzheimers Disease$320,825
R01 · FY2016 · AG · contact PI
Mechanism and therapy of AB-42-specific gamma-secretase$560,012
R01 · FY2015 · NS
Role of TFEB in Tauopathy$419,383
R01 · FY2015 · NS · contact PI
Pathophysiology of APP in vivo$385,034
R01 · FY2015 · AG · contact PI
Knockin Mouse Models of Alzheimers Disease$311,200
R01 · FY2015 · AG · contact PI
Mechanism and therapy of AB-42-specific gamma-secretase$554,411
R01 · FY2014 · NS
Pathophysiology of APP in vivo$396,943
R01 · FY2014 · AG · contact PI
Knockin Mouse Models of Alzheimers Disease$320,825
R01 · FY2014 · AG · contact PI
Mechanism and therapy of AB-42-specific gamma-secretase$540,410
R01 · FY2013 · NS
Pathophysiology of APP in vivo$396,943
R01 · FY2013 · AG · contact PI
Knockin Mouse Models of Alzheimers Disease$303,180
R01 · FY2013 · AG · contact PI
Role of APP in Synaptic Regulation$282,973
R01 · FY2013 · AG · contact PI
Mechanism and therapy of AB-42-specific gamma-secretase$560,010
R01 · FY2012 · NS
Knockin Mouse Models of Alzheimers Disease$320,825
R01 · FY2012 · AG · contact PI
Role of APP in Synaptic Regulation$299,442
R01 · FY2012 · AG · contact PI
Pathophysiology of APP in vivo.$299,442
R01 · FY2012 · AG · contact PI
Mechanism and therapy of AB-42-specific gamma-secretase$574,639
R01 · FY2011 · NS
Pathophysiology of APP in vivo.$299,442
R01 · FY2011 · AG · contact PI
Role of APP in Synaptic Regulation$299,442
R01 · FY2011 · AG · contact PI
Developmental and Pathological Effects of Presenilin$286,761
R01 · FY2011 · AG · contact PI
Role of APP in Synaptic Regulation$311,528
R01 · FY2010 · AG · contact PI
Pathophysiology of APP in vivo.$311,528
R01 · FY2010 · AG · contact PI
Developmental and Pathological Effects of Presenilin$298,337
R01 · FY2010 · AG · contact PI
Role of APP in Synaptic Regulation$314,675
R01 · FY2009 · AG · contact PI
Pathophysiology of APP in vivo.$314,675
R01 · FY2009 · AG · contact PI
Developmental and Pathological Effects of Presenilin$301,350
R01 · FY2009 · AG · contact PI
Pathophysiology of APP in vivo.$314,675
R01 · FY2008 · AG · contact PI
Developmental and Pathological Effects of Presenilin$301,350
R01 · FY2008 · AG · contact PI
Presenilins in tumorigenesis and neurodegeneration$329,997
R01 · FY2007 · NS · contact PI
Developmental and Pathological Effects of Presenilin$307,500
R01 · FY2007 · AG · contact PI
Defining presenilin-beta-catenin pathway in vivo$349,038
R01 · FY2006 · AG · contact PI
Presenilins in tumorigenesis and neurodegeneration$339,853
R01 · FY2006 · NS · contact PI
Developmental and Pathological Effect of Presenilin$320,747
R01 · FY2006 · AG · contact PI
Defining presenilin-beta-catenin pathway in vivo$357,438
R01 · FY2005 · AG
Presenilins in tumorigenesis and neurodegeneration$348,031
R01 · FY2005 · NS
Developmental and Pathological Effect of Presenilin$328,466
R01 · FY2005 · AG
Defining presenilin-beta-catenin pathway in vivo$357,438
R01 · FY2004 · AG
Presenilins in tumorigenesis and neurodegeneration$348,031
R01 · FY2004 · NS
Developmental and Pathological Effect of Presenilin$328,466
R01 · FY2004 · AG
Defining presenilin-beta-catenin pathway in vivo$357,438
R01 · FY2003 · AG
Developmental and Pathological Effect of Presenilin$328,466
R01 · FY2003 · AG
PRESENILIN-1 IN DEVELOPMENT AND AGING$299,000
R01 · FY2003 · NS
Defining presenilin-beta-catenin pathway in vivo$357,438
R01 · FY2002 · AG
Developmental and Pathological Effect of Presenilin$328,466
R01 · FY2002 · AG
PRESENILIN-1 IN DEVELOPMENT AND AGING$299,000
R01 · FY2002 · NS
PRESENILIN-1 IN DEVELOPMENT AND AGING$299,000
R01 · FY2001 · NS
PRESENILIN-1 IN DEVELOPMENT AND AGING$298,250
R01 · FY2000 · NS